黑龙江珍宝岛药业股份有限公司2025年第三次临时股东会决议公告

Core Viewpoint - The company held its third extraordinary general meeting of shareholders for 2025, where no resolutions were rejected, and key decisions were made regarding the appointment of auditors and adjustments to the convertible bond exchange price [2][4][6]. Group 1: Meeting Details - The extraordinary general meeting was held on December 11, 2025, in Harbin, China [2]. - The meeting was convened by the board of directors and chaired by Chairman Fang Tonghua, utilizing a combination of on-site and online voting methods [2][3]. - All six current directors and the board secretary attended the meeting [3]. Group 2: Resolutions and Voting - A resolution to reappoint the auditing firm for the 2025 fiscal year was passed [4]. - There were no significant matters requiring a vote from shareholders holding less than 5% of shares [4]. Group 3: Legal Oversight - The meeting was witnessed by Beijing Lantai Law Firm, with lawyers Zhang Buyong and Cao Wenwen providing legal opinions confirming the legality of the meeting's procedures and outcomes [5]. Group 4: Convertible Bond Adjustment - The controlling shareholder, Heilongjiang Chuangda Group, announced an adjustment to the exchange price of its non-publicly issued convertible bonds due to a decline in the stock price [6]. - The exchange price will be reduced from 10.54 CNY per share to 9.49 CNY per share, effective December 18, 2025, following a period where the stock price was below the original exchange price for 15 consecutive trading days [6].